Clinical trials: Leukoencephalopathies
Alzheimer's Disease or Vascular Dementia
A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia
A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient with Alzheimer's Disease or Vascular Dementia
- Trial name
- NCT02886494
- Testing
- BAC treatment, Matched vehicle
- Where
- 10 sites in United States
- Volunteers
- 80 people
- Sponsor
- Charsire Biotechnology Corp.
Mild Cognitive Impairment, Alzheimer's Disease
Korea Alzheimer's Disease Neuroimaging Initiative
PRIMARY OBJECTIVES -Establish a registry for Alzheimer's disease (AD) and subcortical ischemic vascular dementia (SIVD) STUDY DESIGN -This is a non-randomized, natural history, observational, registry study.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Subcortical Vascular Dementia
- Trial name
- K-ADNI (NCT01979419)
- Where
- South Korea
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Korean Alzheimers' Disease Neuroimaing Intitiative
Mild Cognitive Impairment, Alzheimer Disease
A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
This study seeks to evaluate the efficacy and safety of NA-83 in subjects with mild cognitive impairment due to Alzheimer's Disease
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Alzheimer Dementia, Dementia, Vascular
- Trial name
- NCT03538522
- Testing
- N-831(Traneurocin) 10 mg QD, NA-831 (Traneurocin) 20 mg QD, NA-831 (Traneurocin) 40 mg QD
- Where
- 2 sites in New Zealand
- Volunteers
- 126 people
- Sponsor
- Biomed Industries, Inc.
Adrenomyeloneuropathy Without Cerebral Involvement
Epidural Spinal Cord Stimulation for Lower-limb Impairment in Adrenomyeloneuropathy
Adrenal spinal neuropathy (AMN) is a rare X-linked genetic disease caused by mutations in the ABCD1 gene, and belongs to a special type of adrenal leukodystrophy.
- Trial name
- EPIC-AMN (NCT06796920)
- Testing
- Spinal cord stimulation
- Where
- 4 sites in China
- Volunteers
- 10 people
- Sponsor
- Third Military Medical University
Canavan Disease
Canavan-Single Patient IND
A recombinant virus vector constructed from adeno-associated virus (AAV) has been engineered to carry the human aspartoacylase (ASPA) gene expressed from a modified CMV-enhancer chicken β-actin (CB6) promoter.
- Trial name
- NCT05317780
- Testing
- rAAV9-CB6-AspA
- Where
- United States
- Sponsor
- University of Florida
Mild Cognitive Impairment, Alzheimer's Disease
The Swedish BioFINDER Study
The present study aims at combining biochemical methods with various types of imaging techniques to identify the pathophysiology of Alzheimer's disease (AD).
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Dementia With Lewy Bodies, Vascular Dementia
- Trial name
- NCT01208675
- Where
- 2 sites in Sweden
- Volunteers
- 1,150 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Dementia, Mixed, Dementia, Vascular
Statins in Reducing Events in the Elderly Mind (STAREE-Mind) Imaging Substudy
The STAREE-Mind imaging sub-study will examine the effect of statin treatment over a 4-year period, compared with placebo, on markers of brain health.
- Conditions
- Dementia, Mixed, Dementia, Vascular, Dementia of Alzheimer Type, Cognitive Decline
- Trial name
- STAREE-Mind (NCT05586750)
- Testing
- Atorvastatin 40 Mg Oral Tablet
- Where
- 2 sites in Australia
- Volunteers
- 341 people, healthy volunteers welcome
- Sponsor
- Monash University
Late Infantile Metachromatic Leukodystrophy
Long-term Metazym Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)
This is a single center, open-label study of patients with late infantile MLD. All patients were previous treated 26 weeks in the phase I trial (EudraCT number: 2006-005341-11, NCT00418561).
- Trial name
- NCT00633139
- Testing
- Recombinant human Arylsulfatase A (rhASA)
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Shire
Dementia, Vascular, Alzheimer Dementia
Accurate WiFi-Based Localization of Dementia Patients For Caregiver Support:
In this Phase II SBIR project we will enhance a wireless WiFi-based insole that was designed and successfully tested during a Phase I trial with elderly persons with dementia and their caregivers, and then investigate its…
- Conditions
- Dementia, Vascular, Alzheimer Dementia, Lewy Body Dementia With Behavioral Disturbance
- Trial name
- NCT03360019
- Testing
- Activlink insole, Activlink Phone Application
- Where
- 2 sites in United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Florida
ALD (Adrenoleukodystrophy)
Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)
A randomized open-label Phase 2a study to assess the pharmacokinetics and pharmacodynamic parameters of PXL065 after 12 weeks of treatment in male subjects with adrenomyeloneuropathy (AMN).
- Trial name
- NCT05200104
- Testing
- PXL065
- Sponsor
- Poxel SA
Dementia, Dementia, Vascular
Enhancing Care Coordination: Hospital to Home for Cognitively Impaired Older Adults and Their Caregivers
Aim 1. To compare across three hospital sites the effects on health and cost outcomes observed by the following three interventions, each designed to enhance adaptation and improve outcomes of hospitalized cognitively impaired…
- Conditions
- Dementia, Dementia, Vascular, Alzheimer Disease, Delirium, Dementia, Amnestic, Cognitive Disorders
- Trial name
- NCT00294307
- Testing
- Augmented Standard Care (ASC), Resource Nurse Care (RNC), Advanced Practice Nurse Care (APNC)
- Where
- 3 sites in United States
- Volunteers
- 814 people
- Sponsor
- University of Pennsylvania
Dementia, Alzheimer Disease
All About Me: An Intervention to Ease the Transition to Long Term Care
This Phase I study will involve initial development and evaluation of an innovative cross-platform software app called All About Me (AAM), which will consist of Serious Digital Health Games (SDHGs) for PWD.
- Conditions
- Dementia, Alzheimer Disease, Dementia, Vascular, Dementia, Mixed
- Trial name
- AAM (NCT05516134)
- Testing
- SAFE at Home
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Hopeful Aging
Alzheimer Disease, Mild Cognitive Impairment
Novel Diagnostic and Disease Stage Biomarkers in AD
This study will investigate the efficacy of novel biomarkers, namely blood-based biomarkers, pupillometry and actigraphy to track and predict progression of Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Neuro-Degenerative Diseases, Vascular Dementia
- Trial name
- TRACK-AD (NCT05175664)
- Testing
- Long-term study, Short-term study, Cross-sectional study
- Where
- Denmark
- Volunteers
- 350 people
- Sponsor
- Danish Dementia Research Centre
Dementia, Alzheimer Disease
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia
The purpose of the study is to compare the safety and efficacy of risperidone (an antipsychotic medication) to that of placebo in the treatment of behavioral disturbances associated with dementia.
- Conditions
- Dementia, Alzheimer Disease, Dementia, Vascular
- Trial name
- NCT00249145
- Testing
- risperidone
- Volunteers
- 349 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Mild Cognitive Disorder, Alzheimer Disease
Digital Dementia Registry Bavaria (digiDEM Bayern): a Multicentre, Prospective, Longitudinal Register Study Including People With Mild Cognitive Impairment and Dementia as Well as Their Family Caregivers
Around 57 million people worldwide live with dementia, with approximately 10 million new cases diagnosed each year. By the end of 2023, around 1.8 million people were living with dementia in Germany, the majority of whom were…
- Conditions
- Mild Cognitive Disorder, Alzheimer Disease, Vascular Dementia, Dementia in Other Diseases Classified Elsewhere
- Trial name
- digiDEM Bayern (NCT07721701)
- Where
- 12 sites in Germany
- Volunteers
- 5,000 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Vascular Dementia
Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia.
Study purpose: evaluate clinical efficacy ands afety of Prospekta in the treatment of cognitive, behavioral and psychiatric disorders in patients with vascular dementia.
- Trial name
- NCT04552041
- Testing
- Prospekta
- Where
- 33 sites in Russia
- Volunteers
- 406 people
- Sponsor
- Materia Medica Holding
Krabbe Disease
Krabbe Disease Global Patient Registry
The purpose of this study is to develop a clinical database of individuals diagnosed with Krabbe disease in order to determine which symptoms herald the onset of clinical disease in the various phenotypes of Krabbe disease; to…
- Trial name
- NCT02993796
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- State University of New York at Buffalo
Canavan Disease
A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)
The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease.
- Trial name
- NCT04998396
- Testing
- AAV9 BBP-812
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Aspa Therapeutics
Cognitive Decline, Dementia, Vascular
Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet in Stroke Patients Patients
To test the effects of a 2- to 3-year intervention of the MIND diet versus usual post-stroke care on cognitive decline, the characteristic feature of dementia, and on brain biomarkers of Alzheimer's Disease (AD) and vascular…
- Conditions
- Cognitive Decline, Dementia, Vascular, Alzheimer Disease, Dementia
- Trial name
- NCT04337255
- Testing
- Behavioral Dietary intervention ( MIND Diet), Behavioral Usual Care Diet Intervention
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- Rush University Medical Center
X-Linked Adrenoleukodystrophy (X-ALD), Cerebral Adrenoleukodystrophy (CALD)
Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)
Study ALD-103 will be a multi-site, global, prospective and retrospective data collection study that is designed to evaluate outcomes of allo-HSCT in male subjects with CALD ≤17 years of age.
- Conditions
- X-Linked Adrenoleukodystrophy (X-ALD), Cerebral Adrenoleukodystrophy (CALD), Adrenoleukodystrophy (ALD)
- Trial name
- NCT02204904
- Testing
- Allo-HSCT
- Where
- 13 sites in United States, Argentina and 5 more
- Volunteers
- 59 people
- Sponsor
- Genetix Biotherapeutics Inc.